Drug development, review and public reimbursement in Canada

In this episode, Kelly Lendvoy, VP Communications & Public Affairs speaks to ACE’s Founder and President, Cheryl Koehn, about the long and winding road towards drug development, review and public reimbursement in Canada. They discuss the highlights from a recently published JointHealth™ insight: the phases of drug development, the drug review process, price negotiations, and how it affects the lives of people living with inflammatory arthritis.Additional learning resourcesJointHealth™ insight – From discovery to the patient: The long and winding road towards drug development, review and public reimbursement in CanadaInfographic: Canada drug review process at a glanceACE Arthritis Medications Report Card